300750 Contemporary Amperex Technology (A)

DGAP-News: EBD Group: Record attendance of 4,400 life sciences executives at BIO-Europe(R) 2019 25th annual celebration in Hamburg

DGAP-News: EBD Group / Key word(s): Conference
EBD Group: Record attendance of 4,400 life sciences executives at BIO-Europe(R) 2019 25th annual celebration in Hamburg
21.11.2019 / 14:00
The issuer is solely responsible for the content of this announcement.


Record attendance of 4,400 life sciences executives at BIO-Europe(R) 2019 25th annual celebration in Hamburg

Hamburg and Munich, Germany - November 21, 2019: The highly anticipated 25th annual international life sciences partnering conference wrapped up in Hamburg, Germany, last week with an all-time high 4,400 attendees from 2,300 companies and 61 countries, engaging in 27,375 one-to-one partnering meetings, a five percent increase over 2018.

The event, in Hamburg for the third time, was produced by EBD Group and supported by regional hosts Life Science Nord, the City of Hamburg, and the State of Schleswig-Holstein.

"We were very happy to bring our 25th annual BIO-Europe to Hamburg. Thank you to the regional hosts for their invaluable contributions to the overwhelming success of the conference in facilitating favorable deals among biotech, pharma and investment executives toward the development of therapies and cures," said Anna Chrisman, Managing Director of Informa Connect Life Sciences and Pharma. "We look forward to another great event in Munich, Germany, in 2020." 

Dr. Hinrich Habeck, Managing Director of Life Science Nord, said, "It was an honor for Life Science Nord and our industrial partners Eppendorf, Evotec, Nordmark and Indivumed to have BIO-Europe celebrate its 25th anniversary here in Hamburg. As this year's regional host, it was a perfect opportunity to showcase Northern Germany's strengths in biotech and pharma to an international audience. We are very satisfied with three exciting conference days and we hope to welcome BIO-Europe here very soon." 

The event program highlighted emerging pharma, women's health, the China market, trends in gene therapy, the microbiome, European biotech market access, partnering in immuno-oncology, term sheet negotiations, and digital medicine. Look for detailed coverage soon on .  

The annual Startup Slam pitch competition highlighting the innovations of very early-stage biotechs, sponsored by Johnson & Johnson Innovation with support from Labiotech.eu, Innovation Forum and German Accelerator, was won by Eisbach Bio, with the audience choice award going to Asgard Therapeutics AB.

will be held in Munich, Germany, October 26-28, 2020. Prof. Dr. Horst Domdey, Managing Director of BioM Biotech Cluster Development, regional host in 2020, commented, "BIO-Europe 2019 Hamburg again raised the bar; its success will be hard to beat. But Munich is looking forward to accepting the challenge, especially because it is accompanied with the good wishes from our friends in Hamburg."

For springtime partnering, be sure to consider , March 23-25 in Paris, France. 

# # # 

About EBD Group 

EBD Group's overriding mission is to help collaborations get started across the life sciences value chain. Our range of partnering conferences has grown to become the largest and most productive conference platform in the industry. Each one of our landmark events held in key life sciences markets around the world is powered by our state-of-the-art partnering software, , that enables delegates to efficiently identify and engage with new opportunities via one-to-one meetings.

Today our events (BIO-Europe(R), BIO-Europe Spring(R), BioPharm America(TM), Biotech Showcase(TM), China Showcase, Digital Medicine & Medtech Showcase, ChinaBio(R) Partnering Forum, Rare Disease Innovation and Partnering Summit, and BioEquity Europe) annually attract more than 15,000 senior life sciences executives who engage in over 50,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry.

Tune into EBD Group's Partnering Insight for timely coverage of news that influences the business strategies of the life sciences industry. EBD Group is an Informa company. For more information please visit.

Media contact:

Kari Bennett, EBD Group: ;

European media support:

Anne Hennecke, MC Services AG: 22;

 



21.11.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at


918597  21.11.2019 

fncls.ssp?fn=show_t_gif&application_id=918597&application_name=news&site_id=research_pool
EN
21/11/2019

Underlying

300750Contemporary Amperex Technology (A)

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Contemporary Amperex Technology (A)

 PRESS RELEASE

DGAP-News: ADL Bionatur Solutions Wins New Fermentation Client With Co...

DGAP-News: ADL Bionatur Solutions / Key word(s): Agreement ADL Bionatur Solutions Wins New Fermentation Client With Contract Revenues of EUR 20 Million 02.12.2019 / 09:06 The issuer is solely responsible for the content of this announcement. ADL BIONATUR SOLUTIONS WINS NEW FERMENTATION CLIENT WITH CONTRACT REVENUES OF EUR 20 MILLION The agreement with a leading Swiss biotech company includes technology transfer, upscaling and industrial-scale production of high value-added innovative ingredients for the cosmetics and nutrition industry ADL to apply its expertise in a...

 PRESS RELEASE

Admission of Security to Trading

NEX Exchange (NEXX) Admission of Security to Trading 02-Dec-2019 / 07:30 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. The following security will be admitted to trading on the NEX Exchange Growth Market with effect from 08:00, 02/12/2019. Name of Issuer: Dozens Savings Plc 5.00% Secured Bonds due 2 December 2020 ISIN: GB00BL1GTZ11  Symbol: DS04 EMS: 1 The Regulation Department NEX Exchange London Fruit & Wool Exchange 1 Duval Square London E1 6PW Tel: 020 7858 1655 Email:   W...

 PRESS RELEASE

Admission of Security to Trading

NEX Exchange (NEXX) Admission of Security to Trading 02-Dec-2019 / 07:30 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. The following security will be admitted to trading on the NEX Exchange Growth Market with effect from 08:00, 02/12/2019. Name of Issuer: SAPO PLC Ordinary Shares of GBP 0.01 ISIN: GB00B16GQJ90 Symbol: SAPO EMS: 5000 The Regulation Department NEX Exchange London Fruit & Wool Exchange 1 Duval Square London E1 6PW Tel: 020 7858 1655 Email:   Website: ...

 PRESS RELEASE

EQS-News: LIWET HOLDING AG publishes open letter to Dr. Martin Haefner...

EQS Group-News: Dynamics Group AG / Key word(s): Statement/Corporate Action LIWET HOLDING AG publishes open letter to Dr. Martin Haefner in various Swiss Sunday newspapers 01.12.2019 / 05:59 Open letter to Dr. Martin Haefner Dear Mr Haefner We share your concern about the future of Schmolz+Bickenbach (S+B). The company urgently needs money, everyone - including Liwet - agrees. However, there is still time to find a constructive solution for S+B that is in the interest of all, not only one particular shareholder. Liwet is ready to rescue the company and the 10,000 jobs. Liw...

 PRESS RELEASE

EQS-News: LIWET HOLDING AG publiziert offenen Brief an Dr. Martin Haef...

EQS Group-News: Dynamics Group AG / Schlagwort(e): Stellungnahme/Kapitalmaßnahme LIWET HOLDING AG publiziert offenen Brief an Dr. Martin Haefner in verschiedenen Schweizer Sonntagszeitungen 01.12.2019 / 05:59 Offener Brief an Dr. Martin Haefner Sehr geehrter Herr Haefner Wir teilen Ihre Sorge um die Zukunft von Schmolz+Bickenbach (S+B). Die Firma braucht dringend Geld; damit sind alle - auch Liwet - einverstanden. Noch bleibt Zeit, um eine konstruktive Lösung für S+B zu finden, die im Interesse aller Aktionäre ist, nicht nur eines einzigen. Liwet steht bereit, die Fir...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch